Table 1.
Serious adverse events reported in Italy and other European countries for fexofenadine between 1 January 2010–30 June 2020.
| Personal data |
Role of the drug |
||||||
|---|---|---|---|---|---|---|---|
| Number of AEs | Female N (%) | Male N (%) | Age mean (SD) | Primary suspect N (%) | Secondary suspect N (%) | Interacting N (%) | |
| Italy | 13 | 11 (85) | 2 (15) | 34.2 (21.1) | 7 (54) | 6 (46) | 0 (0) |
| Belgium | 2 | 2 (100) | 0 (0) | 46.5 (2.1) | 2 (100) | 0 (0) | 0 (0) |
| Finland | 3 | 2 (67) | 1 (33) | 58.7 (21.2) | 3 (100) | 0 (0) | 0 (0) |
| Portugal | 4 | 2 (50) | 2 (50) | 41.8 (20.5) | 4 (100) | 0 (0) | 0 (0) |
| Switzerland | 5 | 4 (80) | 1 (20) | 41.8 (22.6) | 3 (60) | 2 (40) | 0 (0) |
SD, standard deviation.
Hungary is not shown as there were no suspected AEs reported